Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin After Large Myocardial Infarction (REVEAL) trial

BACKGROUND: Acute myocardial infarction (MI) remains a leading cause of death despite advances in pharmacologic and percutaneous therapies. Animal models of ischemia/reperfusion have demonstrated that single-dose erythropoietin (EPO) may reduce infarct size, decrease apoptosis, and increase neovascu...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Melloni, Chiara, Rao, Sunil V., Povsic, Thomas J., Melton, Laura, Kim, Raymond J., Kilaru, Rakhi, Patel, Manesh, Talan, Mark, Ferrucci, Luigi, Longo, Dan L., Lakatta, Edward G., Najjar, Samer S., Harrington, Robert A.
Format: Artigo
Langue:Inglês
Publié: 2010
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3018783/
https://ncbi.nlm.nih.gov/pubmed/21095264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ahj.2010.09.007
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires